Immune-Mediated Adverse Events Associated with Ipilimumab CTLA-4 Blockade Therapy: The Underlying Mechanisms and Clinical Management

Immunomodulation with the anti-CTLA-4 monoclonal antibody ipilimumab has been shown to extend overall survival (OS) in previously treated and treatment-naive patients with unresectable stage III or IV melanoma. Blockade of CTLA-4 signaling with ipilimumab prolongs T-cell activation and restores T-ce...

Descripción completa

Detalles Bibliográficos
Autor principal: Tarhini, Ahmad
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Hindawi Publishing Corporation 2013
Materias:
Review Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3820355/
https://www.ncbi.nlm.nih.gov/pubmed/24278787
http://dx.doi.org/10.1155/2013/857519

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3820355/
https://www.ncbi.nlm.nih.gov/pubmed/24278787
http://dx.doi.org/10.1155/2013/857519

Ejemplares similares